These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
10x Genomics slashed its FY24 revenue guidance from $640 million-$5660 million to $595 million-$605 million.10x Genomics, Inc. (NASDAQ:TXG) reported a loss for the third quarter on Tuesday.
10x genomics公司（納斯達克：TXG）週二報告第三季度虧損。
The company posted a quarterly loss of 30 cents per share, compared to market expectations for a loss of 34 cents per share. The company reported quarterly sales of $151.654 million which missed the analyst consensus estimate of $158.632 million.
該公司每股季度虧損30美分，而市場預期爲每股34美分的虧損。公司季度銷售額爲15165.4萬美元，低於分析師對15863.2萬美元的一致預期。
"Our results this quarter fell short of our expectations given greater-than-anticipated disruption from the sales restructuring we implemented in the quarter and cautious customer spending. As these dynamics persist, especially under a difficult macro backdrop, our revenue growth this year will be lower than our previous expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Despite these challenges, I am confident that the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies to reach the full potential of the large opportunity ahead."
「由於我們在本季度實施的銷售重組帶來的干擾超出預期，以及客戶謹慎的支出，本季度的業績未達預期。隨着這些動態的持續存在，尤其在複雜的宏觀背景下，今年我們的營業收入增長將低於之前的預期，」 10x Genomics的聯合創始人兼CEO Serge Saxonov說。「儘管面臨這些挑戰，我相信我們正在採取的措施將使我們能夠觸及更多客戶，跨產品系列實現一致執行，並推動我們的技術廣泛民主化，以發揮前景巨大的潛力。」
10x Genomics slashed its FY24 revenue guidance from $640 million-$5660 million to $595 million-$605 million.
10x Genomics將其FY24營收指導從64000萬美元至566000萬美元下調至59500萬美元至60500萬美元。
10x Genomics shares gained 6.3% to trade at $16.79 on Wednesday.
10x genomics股票週三上漲6.3％，報價16.79美元。
These analysts made changes to their price targets on 10x Genomics following earnings announcement.
這些分析師根據公司的業績公告對10x genomics的目標價進行了調整。
- UBS analyst Dan Leonard maintained 10x Genomics with a Neutral and lowered the price target from $25 to $20.
- JP Morgan analyst Rachel Vatnsdal maintained the stock with a Neutral and lowered the price target from $20 to $14.
- Goldman Sachs analyst Matthew Sykes maintained 10x Genomics with a Sell and cut the price target from $16 to $14.
- Citigroup analyst Patrick Donnelly maintained 10x Genomics with a Buy and cut the price target from $35 to $23.
- 瑞銀分析師丹·萊納德維持對10x genomics的中立評級，並將目標價從25美元降至20美元。
- 摩根大通分析師瑞切爾·瓦特斯達爾維持該股票的中立評級，並將目標價從20美元降至14美元。
- 高盛分析師Matthew Sykes維持對10x genomics的賣出評級，將價格目標從16美元調降至14美元。
- 花旗集團分析師Patrick Donnelly維持對10x genomics的買入評級，將價格目標從35美元調降至23美元。
Considering buying TXG stock? Here's what analysts think:
考慮購買TXG股票嗎？這是分析師的看法：
Read More:
閱讀更多：
Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October
十月份可能拯救您投資組合的前三家科技和電信股票
譯文內容由第三人軟體翻譯。
